8-K: Stereotaxis to Acquire Access Point Technologies in Strategic Move

Stereotaxis, Inc. has agreed to acquire Access Point Technologies EP, Inc., a company specializing in diagnostic catheters, in a deal expected to close in the third quarter of 2024.

Summary

• Stereotaxis, Inc. has entered into a Share Purchase Agreement to acquire Access Point Technologies EP, Inc. (APT).
• The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions.
• The upfront consideration will be paid in Stereotaxis common stock, with additional stock consideration based on earnout provisions.
• Earnout targets are based on global and US revenue targets for APT products and regulatory approvals of robotically-navigated catheters.
• Stereotaxis anticipates filing a resale registration statement for approximately 6.1 million shares of common stock.
• The exact number of shares issued will depend on the average closing price of Stereotaxis stock prior to closing and the achievement of milestones.
• The acquisition is subject to conditions including APT shareholder approval, no material adverse effect on APT, and completion of debt restructuring by the seller.
• APT has agreed to restrictions on soliciting alternative acquisition proposals and will pay a $1.0 million termination fee in certain circumstances.
• Stereotaxis and certain APT shareholders have entered into a voting and support agreement to ensure the acquisition is approved.
• Stereotaxis held its Annual Meeting of Shareholders on May 15, 2024, where a director was elected and proposals to ratify the appointment of Ernst & Young LLP and increase the number of shares authorized under the stock incentive and employee stock purchase plans were approved.

Sentiment

Score: 7

Explanation: The document indicates a strategic acquisition that could be beneficial for Stereotaxis, but there are risks and uncertainties associated with the deal. The shareholder meeting results were positive, but the overall sentiment is cautiously optimistic.

Positives

• The acquisition of APT expands Stereotaxis's portfolio with differentiated high-quality diagnostic catheters.
• The earnout structure aligns incentives for APT's performance post-acquisition.
• The voting and support agreement increases the likelihood of the acquisition being approved.
• Shareholders approved all proposals at the Annual Meeting, indicating support for management's initiatives.
• The increase in authorized shares for the stock incentive and employee stock purchase plans provides flexibility for future compensation and growth.

Negatives

• The acquisition is subject to customary closing conditions, which could delay or prevent the deal from closing.
• The exact number of shares to be issued is dependent on the share price of Stereotaxis stock and the achievement of milestones, creating uncertainty.
• The earnout structure introduces potential dilution for existing shareholders if milestones are met.
• APT is required to pay a $1.0 million termination fee in certain circumstances, indicating potential risks if the deal falls through.

Risks

• The acquisition is subject to customary closing conditions, including regulatory approvals and the absence of a material adverse effect on APT.
• The earnout structure introduces uncertainty regarding the final number of shares to be issued.
• The potential for a $1.0 million termination fee if APT breaches certain obligations.
• The acquisition may not achieve the expected synergies or financial benefits.
• The integration of APT's business into Stereotaxis may present challenges.

Future Outlook

The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions. The company anticipates filing a resale registration statement for the shares issued in the acquisition. The earnout period extends to the end of the calendar quarter following the fifth anniversary of the acquisition closing date.

Industry Context

This acquisition reflects a trend of consolidation in the medical device industry, where companies seek to expand their product portfolios and market reach through strategic acquisitions. The acquisition of APT, with its focus on diagnostic catheters, aligns with Stereotaxis's existing business in robotic navigation for cardiac procedures.

Comparison to Industry Standards

• The acquisition of a private company by a public company using stock as consideration is a common practice in the medical device industry.
• The use of earnout provisions tied to revenue and regulatory milestones is also a standard practice to align the interests of the acquiring and acquired companies.
• The size of the acquisition, while not disclosed in terms of dollar value, appears to be a strategic move to expand Stereotaxis's product offerings.
• Comparable companies in the medical device space often engage in similar acquisitions to enhance their market position and technological capabilities.

Stakeholder Impact

• Shareholders of Stereotaxis may experience dilution due to the issuance of new shares.
• Employees of APT may experience changes in their roles and responsibilities.
• Customers of both Stereotaxis and APT may benefit from the combined product offerings.
• Suppliers of both companies may see changes in their relationships.
• Creditors of APT will be impacted by the debt restructuring.

Next Steps

• Stereotaxis will file a resale registration statement for the shares issued in the acquisition.
• The acquisition is expected to close in the third quarter of 2024.
• APT will need to obtain shareholder approval for the acquisition.
• APT will need to complete certain debt restructuring.
• APT will need to obtain a lease extension on its principal leased facilities in Minnesota.

Key Dates

Keywords

acquisition, stereotaxis, access point technologies, catheters, share purchase agreement, earnouts, stock issuance, annual meeting, voting agreement, medical devices